An overview of PsoProtect’s current data.
We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.
Summary data from PsoProtect’s first 200 cases.
Cases reported by continent:
Average age: 50 years
Phenotype of psoriasis: 194 (97%) plaque psoriasis, 4 (2%) generalized pustular psoriasis, 3 (1.5%) erythrodema
Average BMI: 30 kg/m2
Average number of days of symptoms from COVID-19: 17 days
Concurrent psoriatic arthritis:
Severity of psoriasis at time of onset of COVID-19 (PGA):
Psoriasis severity change during COVID-19:
Systemic medication for psoriasis at time of onset of COVID-19:
|Standard systemic agent||25|
|Small molecule inhibitor||12|
|Biologic and standard systemic co-therapy||7|